

Oncology Today with Dr Neil Love: Key Presentations on Gastrointestinal Cancers from the 2021 ASCO Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following outcomes was reported at ASCO 2021 from the KEYNOTE177 study evaluating pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer?
 - a. A statistically significant improvement in overall survival
 - b. No statistically significant improvement in overall survival
2. Results presented at ASCO 2021 of the Phase III CheckMate 577 trial of adjuvant nivolumab for patients with resected esophageal or gastroesophageal junction cancer demonstrated an improvement in comparison to placebo in which of the following endpoints?
 - a. Disease-free survival but not distant metastasis-free survival
 - b. Distant metastasis-free survival but not disease-free survival
 - c. Both disease-free survival and distant metastasis-free survival
3. Analysis of the IMbrave150 study to determine the association between treatment response and overall survival among patients with unresectable hepatocellular carcinoma receiving atezolizumab with bevacizumab reported which of the following observations?
 - a. A correlation between overall survival and partial or complete response
 - b. No correlation between overall survival and partial or complete response
4. A presentation at ASCO 2021 of the study by Scharn and colleagues investigating the efficacy of the bispecific antibody zenocutuzumab for advanced pancreatic cancer and other solid tumors reported promising activity in patients with pancreatic cancer with which alterations?
 - a. KRAS mutations
 - b. NRG1 fusions
 - c. BRCA mutations